Founder and CEO, Longevity Vision Fund
7 Signs of Longevity Revolution
Sergey Young is the founder of Longevity Vision Fund, a venture fund that invests in technologies with the potential to disrupt life sciences and healthcare to help people live longer and healthier lives.
Sergey is on the Board of Directors of the American Federation of Aging Research (AFAR) and is the Development Sponsor of upcoming Age Reversal XPRIZE global competition designed to reverse aging.
Sergey is the author of the highly anticipated book ‘The Science and Technology of Growing Young’ released in the US and globally on August 24th, 2021 and is available on Amazon. The book is a science-based look into the future of longevity, which is based on interviews with over 30 longevity pioneers.
Founder and CEO, Insilico Medicine
Converging AI and Ageing Research: Deep learning on longitudinal data for biomarker development, target discovery
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, Inc, a spin-off of Insilico Medicine developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and life insurance industry. In 2020 Deep Longevity was acquired by Regent Pacific resulting in 3X increase in stock price since acquisition. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in Baltimore, Shanghai, Taipei, Hong Kong, Moscow, and St Petersburg, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (GPU company acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Macmillan, 2013). He serves on the editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (8th annual in 2021), the world's largest event on aging in the pharmaceutical industry. He has two undergraduate degrees in computer science from Queen's University (Canada), Masters in Biotechnology from Johns Hopkins, and PhD in Physics and Mathematics from Moscow State University. In December 2020 he developed and launched an online Longevity Medicine Course for Physicians taken by over 3,000 medical professionals. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging. Citizen of Canada permanently residing in Hong Kong.
Ageing Research at King's (ARK) is a cross-faculty multidisciplinary consortium of investigators which brings together scholarship and research in ageing in several complementary areas. ARK represents King’s world class excellence for research on the biology of ageing, from the basic mechanisms in biogerontology and clinical translation to social impact of ageing and technology transfer. The primary purpose of ARK is to enhance multidisciplinary research collaborations within King’s to better understand the mechanisms of ageing, improving health-span and longevity leading to innovation, commercialisation and entrepreneurship. As ageing consists of complex systems at the level of biology, psychology, society and public policy, in order to understand the processes of ageing and the nature of old age itself, it is important to bring together research and innovation from a number of key disciplines. ARK is uniquely positioned to address the challenges of an ageing world, and to provide answers at multiple levels, from cellular mechanisms and therapeutics to health tech innovations and social sciences, facilitated through an academic-industry hub at King's and ARK global partners.